Ozanimod

• PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial. Not authorised
  2025-520955-10-00 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
• A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral oza… Recruiting
  2023-509248-86-00 Phase II/III 5 countries Bristol-Myers Squibb Services Unlimited Company
• Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study Recruiting
  2024-518859-27-00 Phase IV 1 country Azienda Ospedaliera Universitaria Integrata Verona
• Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended
  2023-503190-38-00 Phase II 1 country Antwerp University Hospital
• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn… Ended
  2023-508777-91-00 Phase II/III 6 countries Celgene International II S.a.r.l.
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 Phase III 15 countries Celgene International II SARL
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 Phase III 14 countries Celgene International II S.a.r.l.
• The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the treatment of ulcerative colitis (UC) Ended
  2024-514815-92-00 Phase III 7 countries Celgene International II SARL

Showing 1–8 of 8 trials